![Pluvicto [Lutetium-177-PSMA-617] – (Targeted Radioligand Therapy for Prostate Cancer)](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E)
Introduction
Pluvicto, also known as Lutetium-177-PSMA-617, is a targeted radioligand therapy used to treat metastatic castration-resistant prostate cancer (mCRPC). This advanced treatment targets PSMA (Prostate-Specific Membrane Antigen)-positive cancer cells, delivering radiation directly to the tumor while sparing surrounding healthy tissue.
Purpose
- Treats metastatic castration-resistant prostate cancer (mCRPC).
- Reduces tumor burden and delays disease progression in PSMA-positive patients.
- Provides an option for patients who have exhausted other systemic therapies.
How It Works
Pluvicto combines a PSMA-targeting ligand with Lutetium-177, a radioactive isotope. The ligand binds to PSMA, which is overexpressed on prostate cancer cells, and delivers localized radiation, causing cancer cell death with minimal damage to normal tissues.
Usage
- Administered as an intravenous infusion in a clinical setting every 6 weeks for up to 6 cycles.
- Requires PSMA-positive imaging (e.g., PSMA PET scan) to confirm eligibility for treatment.
- Follow-up includes regular monitoring of blood counts, kidney function, and response to therapy.
Considerations
- Common side effects include fatigue, dry mouth, nausea, and mild bone marrow suppression.
- Rare but serious risks include kidney damage or significant hematologic toxicity.
- Patients with limited bone marrow reserve or poor kidney function require careful assessment.
At Crossroads Urology
At Crossroads Urology, Pluvicto represents the forefront of precision medicine for advanced prostate cancer. Our team works in collaboration with oncology specialists to provide this cutting-edge therapy, ensuring comprehensive support throughout treatment.
Conclusion
Pluvicto [Lutetium-177-PSMA-617] is a groundbreaking treatment for advanced prostate cancer, offering targeted radiotherapy for PSMA-positive tumors. Contact Crossroads Urology today to learn more about this innovative option and how it can fit into your personalized care plan.
